Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

HCW Presentation September 13, 2021

Canaccord Presentation August 12, 2021

Wedbush Presentation August 11, 2021

HCW Presentation March 9, 2021

SVB Leerink Presentation Feb 24, 2021

JPM Presentation Jan 14, 2021

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

1 2 3

Press Releases

ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer

press release

September 22, 2015

Geneva, Switzerland, 22 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more

ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways

press release

September 1, 2015

01 Sep 2015 Geneva, Switzerland, 01 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs…

Read more

ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study – Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women –

press release

June 23, 2015

Geneva, Switzerland, 23 June 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more
1 81 82 83 84 85 86

General Meetings

ObsEva Annual General Meeting 2021

May 28, 2021

Read more

ObsEva Annual General Meeting 2020

June 9, 2020

Read more
1 2 3 4

Upcoming Events

Half Year 2024 Financial Results: 30 September 2024

Event


    Read more

    Annual General Meeting: Thursday 27 June, 2024

    Event


      Read more

      Obseva 2023 Swiss Annual Report: 30 April, 2024

      Event


        Read more
         

        Contacts

        ObsEva Switzerland Office

        Chemin des Aulx,12

        1228, Plan-Les-Ouates, Geneva, Switzerland

        +41 (0)22 552 3840


        contact@obseva.ch

        Investor relations


        IR@obseva.ch

        CEO Office

        +41 (0)22 552 1550


        contact@obseva.ch

         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue